Other Events ·
BridgeBio Pharma, Inc. announced the pricing and launch of a secondary public offering of 5,000,000 shares of common…
BBIOBridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. announced the pricing and launch of a secondary public offering of 5,000,000 shares of common stock by selling stockholder KKR Genetic Disorder L.P. The shares were priced at $78.00 per share, with an expected closing date of August 17, 2026. BridgeBio will not receive any proceeds from the sale and is not issuing new equity. The transaction aims to diversify the company's institutional shareholder base toward high-quality, long-term ownership. This filing discloses a material definitive agreement for the underwriting of these shares via William Blair & Company, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC. BridgeBio Pharma operates in the biopharmaceutical industry, developing medicines for genetic conditions.